GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone240-243-1201
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$20,000.00
Profitability
Miscellaneous
Employees50
Next Earnings Date11/1/2019 (Estimated)
OptionableOptionable
GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions
What is GlycoMimetics' stock symbol?
GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
How were GlycoMimetics' earnings last quarter?
GlycoMimetics Inc (NASDAQ:GLYC) released its earnings results on Thursday, August, 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.01. View GlycoMimetics' Earnings History.
When is GlycoMimetics' next earnings date?
What price target have analysts set for GLYC?
6 brokerages have issued 12 month price objectives for GlycoMimetics' shares. Their predictions range from $5.00 to $35.00. On average, they anticipate GlycoMimetics' stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 370.6% from the stock's current price. View Analyst Price Targets for GlycoMimetics.
What is the consensus analysts' recommendation for GlycoMimetics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GlycoMimetics.
What are Wall Street analysts saying about GlycoMimetics stock?
Here are some recent quotes from research analysts about GlycoMimetics stock:
- 1. According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (8/7/2019)
- 2. HC Wainwright analysts commented, "We base our $23 price target on probability-adjusted forecasts for uproleselan in AML as well as rivipansel in SCD VOC. We use the net present value of our revenue forecast through 2027, apply a 60% POS for AML and a 70% POS for SCD 4x price/sales multiple for AML, and estimated 2019 year-end net cash of $3.11 per share, to arrive at our price target. Our P/S multiple of 4x is inline with GlycoMimetics’ peers that range between 2-5x." (4/12/2019)
Has GlycoMimetics been receiving favorable news coverage?
Media coverage about GLYC stock has trended negative on Sunday, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GlycoMimetics earned a daily sentiment score of -2.3 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for GlycoMimetics.
Who are some of GlycoMimetics' key competitors?
Some companies that are related to GlycoMimetics include Aurinia Pharmaceuticals (AUPH), Synthorx (THOR), Kiniksa Pharmaceuticals (KNSA), Akebia Therapeutics (AKBA), Karuna Therapeutics (KRTX), Endo International (ENDP), Intra-Cellular Therapies (ITCI), Revance Therapeutics (RVNC), Aptorum Group (APM), Viking Therapeutics (VKTX), INDIVIOR PLC/S (INVVY), Sinovac Biotech (SVA), Milestone Pharmaceuticals (MIST), Basilea Pharmaceutica (BPMUF) and Crinetics Pharmaceuticals (CRNX).
What other stocks do shareholders of GlycoMimetics own?
Who are GlycoMimetics' key executives?
GlycoMimetics' management team includes the folowing people:
- Ms. Rachel K. King, Pres, CEO & Director (Age 60)
- Mr. Brian M. Hahn, Sr. VP, CFO & Sec. (Age 45)
- Dr. John L. Magnani, Sr. VP of Research, Chief Scientific Officer & Director (Age 66)
- Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 51)
- Mr. Henry Flanner, VP of Technical Operations
Who are GlycoMimetics' major shareholders?
GlycoMimetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Invesco Ltd. (11.04%), Price T Rowe Associates Inc. MD (7.05%), BlackRock Inc. (6.63%), Vanguard Group Inc. (4.03%), Jennison Associates LLC (3.28%) and Jennison Associates LLC (3.28%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Daniel M Junius, Helen M Thackray, John L Magnani and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.
Which major investors are selling GlycoMimetics stock?
GLYC stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Citadel Advisors LLC, Vanguard Group Inc., Man Group plc, Janus Henderson Group PLC, Janus Henderson Group PLC, Allianz Asset Management GmbH and BlackRock Inc.. View Insider Buying and Selling for GlycoMimetics.
Which major investors are buying GlycoMimetics stock?
GLYC stock was bought by a variety of institutional investors in the last quarter, including Invesco Ltd., Asymmetry Capital Management L.P., Candriam Luxembourg S.C.A., GSA Capital Partners LLP, State Board of Administration of Florida Retirement System, DekaBank Deutsche Girozentrale, Northern Trust Corp and AXA. View Insider Buying and Selling for GlycoMimetics.
How do I buy shares of GlycoMimetics?
Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GlycoMimetics' stock price today?
One share of GLYC stock can currently be purchased for approximately $3.40.
How big of a company is GlycoMimetics?
GlycoMimetics has a market capitalization of $146.85 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-48,270,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe.View Additional Information About GlycoMimetics.
What is GlycoMimetics' official website?
How can I contact GlycoMimetics?
GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]
MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
